Core Insights - Plus Therapeutics, Inc. is set to provide a business update on January 22, 2026, before market opening, followed by a conference call at 9:00 a.m. ET to discuss further details [1] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging central nervous system cancers, aiming to improve clinical outcomes [3] - The company is advancing a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma, utilizing image-guided local beta radiation and targeted drug delivery methods [3] - Plus Therapeutics has established a supply chain through strategic partnerships to facilitate the development, manufacturing, and potential commercialization of its products [3] Subsidiary Information - CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, develops proprietary laboratory-developed tests, including CNSide®, which identifies tumor cells that have metastasized to the central nervous system in carcinoma and melanoma patients [4] - The CNSide® CSF Assay Platform allows for quantitative analysis of cerebrospinal fluid, enhancing the management of patients with leptomeningeal metastases [4]